BA 3142
Alternative Names: BA-3142Latest Information Update: 07 Apr 2023
Price :
$50 *
At a glance
- Originator BioAtla
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD276 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 Apr 2023 BioAtla plans to file an IND application in 2024 (BioAtla pipeline; April 2024)
- 19 May 2021 BA 3142 is available for licensing as of 19 May 2021. https://www.bioatla.com/strategic-relationships/